PCSK9 · GalNAc, SC
Inclisiran (Leqvio)
An approved siRNA therapeutic silencing PCSK9, indicated for Hypercholesterolemia / ASCVD. This page lists what the siRNA Atlas corpus holds on Inclisiran and links to each primary document.
Identity
- Generic name
- Inclisiran
- Brand name
- Leqvio
- Molecular target
- PCSK9
- Indication
- Hypercholesterolemia / ASCVD
- Delivery
- GalNAc, SC
- FDA application
- NDA 214012
- Regulatory coverage
- FDA and EMA
Source documents in the corpus (5)
- FDAFDA prescribing information (current label)
- FDAFDA review
- FDAFDA pharmacology / toxicology review
- EMAEMA public assessment report (EPAR)
- EMAEMA product information (SmPC)
Every answer about Inclisiran is drawn from these documents and the indexed literature, and cites the passage it used. Tables inside them are preserved, so numeric dosing, exposure and toxicology values stay searchable.
Ask the corpus about Inclisiran
- →What is the approved dose and dosing interval of inclisiran (Leqvio)?
- →Describe the clinical pharmacology and ADME of inclisiran.
- →What did the regulatory reviews conclude about the nonclinical safety of inclisiran?
- →Summarise the pivotal trial evidence for inclisiran.
- →How does inclisiran silence PCSK9, and how long does the effect last?
Other approved siRNA therapeutics
Information here is drawn from public regulatory records for reference and research. It is not medical advice — verify any clinical or regulatory decision against the current label and assessment report linked above.